[1]于祥菊,宋碧莹,刘 滢,等.Chk1及其抑制剂调控肿瘤作用机制研究[J].医学信息,2019,(19):39.[doi:10.3969/j.issn.1006-1959.2019.19.013]
 YU Xiang-ju,SONG Bi-ying,LIU Ying,et al.Study on the Mechanism of Chk1 and Its Inhibitors Regulating Tumor[J].Medical Information,2019,(19):39.[doi:10.3969/j.issn.1006-1959.2019.19.013]
点击复制

Chk1及其抑制剂调控肿瘤作用机制研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年19期
页码:
39
栏目:
综述
出版日期:
2019-10-01

文章信息/Info

Title:
Study on the Mechanism of Chk1 and Its Inhibitors Regulating Tumor
文章编号:
1006-1959(2019)19-0039-05
作者:
于祥菊宋碧莹刘 滢吕冬霞
(佳木斯大学,黑龙江 佳木斯 154007)
Author(s):
YU Xiang-juSONG Bi-yingLIU YingLYU Dong-xia
(Jiamusi University,Jiamusi 154007,Heilongjiang,China)
关键词:
Chk1抑制剂肿瘤细胞抑癌基因
Keywords:
Chk1InhibitorTumor cellsTumor suppressor gene
分类号:
R730.5
DOI:
10.3969/j.issn.1006-1959.2019.19.013
文献标志码:
A
摘要:
细胞周期检查点激酶1(Chk1)是由抑癌基因Chk1编码的丝氨酸/苏氨酸(Ser/Thr激酶),广泛存在于哺乳动物细胞内。近年来,多项国内外研究表明Chk1及其抑制剂能调控肿瘤的形成与发展。基于此,本文以Chk1及其抑制剂的概况和应用为基础,总结其多向调控肿瘤细胞的作用机制,旨在为Chk1及其抑制剂的临床应用和开发、相关药物的研发提供参考。
Abstract:
Cell cycle checkpoint kinase 1 (Chk1) is a serine/threonine (Ser/Thr kinase) encoded by the tumor suppressor gene Chk1 and is widely found in mammalian cells. In recent years, a number of domestic and foreign studies have shown that Chk1 and its inhibitors can regulate the formation and development of tumors. Based on this, based on the profile and application of Chk1 and its inhibitors, this paper summarizes the mechanism of multi-directional regulation of tumor cells, aiming to provide reference for the clinical application and development of Chk1 and its inhibitors, and the development of related drugs.

参考文献/References:

[1]Zhang Y,Hunter T.Roles of Chk1 in cell biology and cancer therapy[J].Int J Cancer,2014,134(5):1013-1023. [2]Walker M,Black EJ,Oehler V,et al.Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation by de-repression of Chk1 catalytic activity[J].Oncogene,2009,28(24):2314-2323. [3]Walworth N,Davey S,Beach D.Fission yeast chkl protein kinase links the rad checkpoint pathway to cdc2[J].Nature,1993,363(6427):368-371. [4]Furuya K.DNA checkpoints in fission yeast[J].Journal of Cell Science,2003,116(19):3847-3848. [5]Shimuta K,Nakajo N,Uto K,et al.Chk1 is activated transiently and targets Cdc25A for degradation at the Xenopus midblastula transition[J].The EMBO J,2001,21(14):3694-3703. [6]Collart C,Smith JC,Zegerman P.Chk1 Inhibition of the Replication Factor Drf1 Guarantees Cell-Cycle Elongation at the Xenopus laevis Mid-blastula Transition[J].Developmental Cell,2017,42(1):82-96. [7]Smith J,Larue L,Gillespie DA.Chk1 is essential for the development of murine epidermal melanocytes[J].Pigment Cell Melanoma Res,2013,26(4):580-585. [8]Lunardi A,Varmeh S,Chen M,et al.Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis[J].Cancer Discovery,2015,5(5):550-563. [9]Yuan R,Vos HR,Van RE,et al.Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest[J].Embo Journal,2018,37(5):1-17. [10]O'Connor MJ.Targeting the DNA Damage Response in Cancer[J].Molecular Cell,2015,60(4):547-560. [11]Liu Y,Vidanes G,Lin YC,et al.Characterization of a Saccharomyces cerevisiae homologue of Schizosaccharomyces pombe Chk1 involved in DNA-damage-induced M-phase arrest[J].Mol Gen Genet,2000,262(6):1132-1146. [12]Lam MH,Liu Q,Elledge SJ,et al.Chk1 is haploinsufficient for multiple functions critical to tumor suppression[J].Cancer Cell,2004,6(1):45-59. [13]Signore M,Buccarelli M,Pilozzi E,et al.UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response[J].Oncotarget,2016,7(28):44113-44128. [14]Lien WC,Chen TY,Sheu SY,et al.7-hydroxy-staurosporine,UCN-01,induces DNA damage response, and autophagy in human osteosarcoma U2-OS cells[J].Journal of Cellular Biochemistry,2018,119(6):4729-4741 [15]Luqi W,Yue W,Andy C,et al.Effects of a checkpoint kinase inhibitor,AZD7762,on tumor suppression and bone remodeling[J].International Journal of Oncology,2018,53(3):1001-1012. [16]Park YH,Kim DK,Kim HW,et al.Repositioning of anti-cancer drug candidate,AZD7762,to an anti-allergic drug suppressing IgE-mediated mast cells and allergic responses via the inhibition of Lyn and Fyn[J].Biochem Pharmac,2018,154(1):270-277. [17]Suzuki M,Yamamori T,Bo T,et al.MK-8776,a novel Chk1 inhibitor,exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis[J].Translational Oncology,2017,10(4):491-500. [18]Laquente B,Lopez-Martin J,Richards D,et al.A phase Ⅱ study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients[J].BMC Cancer,2017,17(1):137-146. [19]Wayne J,Brooks T,Massey AJ.Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase[J].Oncotarget,2016,7(51):85033-85048. [20]Walton MI,Eve PD,Hayes A,et al.The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma[J].Oncotarget,2016,7(3):2329-2342. [21]Larocheclary A,Lucchesi C,Rey C,et al.CHK1 Inhibition in Soft-Tissue Sarcomas:Biological and Clinical Implications[J].Annals of Oncology Official Journal of the European Society for Medical Oncology,2018,29(4):1023-1029. [22]Tullio AD,Rouault-Pierre K,Abarrategi A,et al.The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia[J].Nature Communications,2017,8(1):1679. [23]Wayne J,Stokes S,Foloppe N,et al.Identification and preclinical characterisation of VER-250840,a potent,selective Chk1 inhibitor with in vivo oral single-agent antitumor activity [J].Molecular Targets and Cancer Therapeutics,2018,17(1):Abstract nr B163. [24]Deraska P,Reavis H,Labe S,et al.Whole-genome CRISPR/Cas9 screen of the CHK1 inhibitor prexasertib implicates FAM122A loss as a potential resistance mechanism[J].AACR Cancer Res,2018,78(13):4287. [25]Patel R,Barker HE,Kyula J,et al.An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation[J].Radiotherapy and Oncology,2017,122(3):470-475. [26]Zhou ZR,Yang ZZ,Wang SJ,et al.The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy[J].Acta Pharmacol Sin,2017,38(4):513-523. [27]Nie C,Luo Y,Zhao X,et al.Caspase-9 mediates Puma activation in UCN-01-induced apoptosis[J].Cell Death and Disease,2014,5(10):e1495. [28]Wang FZ,Fei HR,Cui YJ,et al.The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest,DNA damage response and autophagy in cancer cells[J].Apoptosis,2014,19(9):1389-1398. [29]Zhang Y,Lai J,Du Z,et al.Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress[J].Oncotarget,2016,7(23):34688-34702. [30]Suzuki M,Yamamori T,Bo T,et al.MK-8776,a novel Chk1 inhibitor,exhibits an improved radiosensitizing effect compared to UCN-01 by exacerbating radiation-induced aberrant mitosis[J].Translational Oncology,2017,10(4):491-500. [31]Barnard D,Diaz HB,Burke T,et al.LY2603618,a selective CHK1 inhibitor,enhances the anti-tumor effect of gemcitabine in xenograft tumor models[J].Investigational New Drugs,2016,34(1):49-60. [32]Vincelette ND,Ding H,Huehls AM,et al.Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivo[J].Scientific Reports,2019,9(1):3617. [33]Preet R,Siddharth S,Satapathy SR,et al.Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade[J].Biochemical Pharmacology,2016,105(1):23-33. [34]Hauge S,Naucke C,Hasvold G,et al.Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage+in S-phase due to distinct regulation of CDK activity and CDC45 loading[J].Oncotarget,2017,8(7):10966-10979. [35]Booth L,Roberts J,Poklepovic A,et al.The Chk1 inhibitor,SRA737,synergizes with niraparib to kill cancer cells via multiple cell death pathways[A]//Proceedings of the American Association for Cancer Research Annual Meeting[C].2018. [36]Yin Y,Shen Q,Zhang P,et al.Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer[J].American Journal of Cancer Research,2017,7(3):473.

相似文献/References:

[1]张文慧,高 丽,黄惠丽,等.蛋白磷酸酶1和2A的研究进展[J].医学信息,2018,(15):20.[doi:10.3969/j.issn.1006-1959.2018.15.009]
 ZHANG Wen-hui,GAO Li,HUANG Hui-li,et al.Progress in the Research of Protein Phosphatase 1 and 2A[J].Medical Information,2018,(19):20.[doi:10.3969/j.issn.1006-1959.2018.15.009]

更新日期/Last Update: 2019-10-01